Bayer's Newly Approved HER2 Lung Cancer Drug: What Is the Pipeline Value of Sevabertinib?

Deep News11-06

Recently, the National Medical Products Administration approved Bayer's Hyrnuo® (sevabertinib tablets) as a monotherapy for adult patients with unresectable locally advanced or metastatic non-small cell lung cancer harboring HER2-activating mutations.

Hyrnuo® is an oral small-molecule tyrosine kinase inhibitor that had previously been approved in China for previously treated HER2-mutant non-small cell lung cancer patients.

This full-line indication approval will further advance precision treatment of HER2-mutant non-small cell lung cancer toward earlier treatment stages.

Non-small cell lung cancer accounts for more than 85% of lung cancers, with approximately 2% to 4% of advanced patients carrying HER2-activating mutations.

The product had received Breakthrough Therapy designation from the Center for Drug Evaluation of the National Medical Products Administration, and its marketing application was also included in priority review.

Sevabertinib can effectively inhibit mutant HER2 and demonstrates high selectivity for mutant EGFR relative to wild-type EGFR.

Using the industry-standard risk-adjusted net present value (rNPV) model as a foundation, combined with publicly available clinical data, the competitive landscape of the therapeutic space, and medical insurance payment expectations, we estimate the pipeline value of this product in the Chinese market to provide a reference valuation benchmark for the market.

The core logic of rNPV valuation is to discount future cash flows over the entire lifecycle of a pipeline to the present after applying multiple risk adjustments. The formula is: rNPV = Peak Sales × Probability of Clinical Success × Discount Factor. And Peak Sales = Total Target Patient Population × Expected Peak Penetration Rate × Market Share × Annual Treatment Cost × Clinical Data Quality Coefficient × Commercialization Rights Coefficient.

Regarding the probability of clinical success, sevabertinib has entered the early commercialization stage, and the core clinical review risks have been substantially resolved. Only confirmatory studies corresponding to conditional approval remain to be completed. Based on industry-standard success rate benchmarks, the probability of clinical success is set at 0.95.

Regarding the total patient population, sevabertinib primarily covers the indication of HER2-activating mutant locally advanced/metastatic non-small cell lung cancer. According to public data from the National Cancer Center and Bayer, there were approximately 828,000 new lung cancer cases in China in 2022, of which non-small cell lung cancer accounted for more than 85%, and advanced patients accounted for approximately 70%. The incidence of HER2-activating mutations in the advanced NSCLC population is 4.3%, with the mutation rate in Asian populations slightly higher than in Europe and the United States. Based on these calculations, the annual number of newly diagnosed patients in China meeting the medication indication is approximately 21,000. Considering that the median survival of patients has significantly improved with the widespread adoption of targeted therapy, the stock of patients under treatment during the peak phase will continue to expand. Combined with improved diagnosis rates driven by increased genetic testing coverage, and after excluding populations unable to tolerate systemic therapy or with severe underlying diseases, the total potential target patient population for sevabertinib in China is approximately 65,000.

Regarding penetration rate, targeted therapy for HER2-mutant NSCLC in China is still in the market introduction phase. Constrained by insufficient genetic testing coverage, nascent medical insurance reimbursement, and limited clinical awareness, the overall treatment penetration rate of the therapeutic space in 2025 is only about 12.4%. In the long term, with the expansion of NGS testing to lower-tier markets, continued expansion of the medical insurance catalog, and upgrading of CSCO guideline recommendation levels, and referencing the penetration rate levels of more than 35% for mature driver targets such as EGFR, it is expected that after the domestic HER2-targeted drug space enters the mature stage, the overall peak penetration rate could reach approximately 32%. Among these, oral small-molecule TKIs, with advantages of convenient administration and high home-treatment compliance, are expected to capture approximately 40% of the market share.

Regarding market share, the current core players in this domestic niche include Daiichi Sankyo/AstraZeneca's trastuzumab deruxtecan (ADC), Hengrui Pharmaceuticals' retlirafusp alfa (domestic ADC), Boehringer Ingelheim's zongertinib (oral TKI), and Bayer's sevabertinib. The number of mainstream competitors is 3-4, with another 5-6 domestic products in late-stage clinical development that have not yet entered red ocean competition. Bayer, as a multinational pharmaceutical company, has a mature nationwide oncology sales network and academic promotion system. Sevabertinib ranks second in research and development progress among oral TKI products and has the advantage of full-indication layout. Considering the competitive landscape and the company's commercialization capabilities, a 25% market share assumption is assigned to sevabertinib.

Regarding annual treatment cost, after the 2026 national medical insurance negotiations, the prices of multiple oncology targeted drugs have dropped significantly. Post-reimbursement annual treatment costs for ADC products in the same space have generally fallen to the range of 180,000 to 250,000 yuan, while oral TKI products are priced significantly lower than injectable ADCs. Considering that sevabertinib is an oral innovative drug with a certain clinical value premium and needs to adapt to the domestic medical insurance payment system, its post-reimbursement annual treatment cost is estimated at approximately 98,000 yuan, positioning it at the upper-middle level among similar oral targeted drugs.

Regarding clinical data quality, according to the SOHO-01 multi-cohort Phase I/II clinical data disclosed by Bayer, sevabertinib achieved an objective response rate (ORR) of 75% and a median progression-free survival (mPFS) of 16.4 months in first-line treatment of HER2-activating mutant advanced NSCLC. In previously treated patients, the ORR reached 73% with an mPFS of 9.6 months. The efficacy ranks in the global first tier of HER2 oral TKIs and demonstrates clear intracranial activity in patients with brain metastases. Overall, its registrational clinical trial adopted an open-label single-arm design without a randomized control group, and the efficacy data approaches best-in-class levels. Therefore, the clinical data quality coefficient is set at 0.68.

Regarding commercialization rights, sevabertinib is a Class 1 innovative drug independently developed by Bayer, with complete development, manufacturing, and commercialization rights in the Chinese market. Academic promotion and channel coverage are handled by Bayer China's own oncology commercialization team, with no external sales royalties payable. Based on the evaluation criteria, the commercialization rights coefficient is set at 0.90. It should be noted that this estimate only covers the Chinese mainland market, and the global rights value of sevabertinib is not included in this rNPV calculation.

Based on the above parameters, the peak annual sales of Hyrnuo® (sevabertinib tablets) in the Chinese market is approximately 310 million yuan. Regarding the discount factor, as Bayer is a mature global large pharmaceutical company with relatively low overall pipeline risk, the corresponding discount rate is set at 11%, within the industry-standard range of 10%-12%. From a time perspective, sevabertinib is expected to achieve medical insurance reimbursement in 2026. Innovative drugs typically require 4-6 years of market ramp-up after reimbursement to reach peak sales, so peak sales are expected around 2032, approximately 6 years from the current point. Using the compound discount formula, the discount factor is approximately 0.53. Combined with the 0.95 probability of clinical success, the final risk-adjusted net present value of Hyrnuo®'s pipeline in the Chinese market is approximately 156 million yuan.

Disclaimer: The peak sales, risk-adjusted net present value, and other data in this article are model estimation results based on publicly available information and a series of subjective assumptions. They are intended solely to illustrate the valuation logic and do not represent official company forecasts or constitute any investment advice. Key parameters such as clinical success rate, penetration rate, market share, and annual treatment cost are subject to significant uncertainty, and actual results may differ materially from the estimated values. Investors should exercise independent judgment and bear investment risks themselves.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment